Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $33.9 million.

  • Tg Therapeutics' Change in Receivables rose 544.54% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.7 million, marking a year-over-year increase of 9586.82%. This contributed to the annual value of $78.1 million for FY2024, which is 5284.29% up from last year.
  • Latest data reveals that Tg Therapeutics reported Change in Receivables of $33.9 million as of Q3 2025, which was up 544.54% from $41.4 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Change in Receivables peaked at $60.9 million during Q1 2025, and registered a low of -$814000.0 during Q2 2022.
  • Its 5-year average for Change in Receivables is $14.7 million, with a median of $10.3 million in 2023.
  • As far as peak fluctuations go, Tg Therapeutics' Change in Receivables tumbled by 60875.0% in 2022, and later soared by 2491363.64% in 2023.
  • Tg Therapeutics' Change in Receivables (Quarter) stood at $5000.0 in 2021, then tumbled by 1860.0% to -$88000.0 in 2022, then skyrocketed by 13478.41% to $11.8 million in 2023, then grew by 14.31% to $13.5 million in 2024, then skyrocketed by 151.66% to $33.9 million in 2025.
  • Its Change in Receivables was $33.9 million in Q3 2025, compared to $41.4 million in Q2 2025 and $60.9 million in Q1 2025.